Pioneering Sustainable Solutions for Vaccine Adjuvants
Evax provides non-animal sources of triterpenes oils and uses them in well known emulsion adjuvants (commercial adjuvant mimics) and in novel, next generation combination adjuvants.
What Sets EVAX Apart?
What Sets EVAX Apart?
Emulsion Adjuvants
Integrated Manufacturing
Using our proprietary yeast-production system we have an integrated, US-based, production pipeline for the critical ingredient in triterpene-containing adjuvants.
EVAX offers the only commercial mimic made with non-animal squalene that is available for preclinical through clinical (GMP) applications.
Translational Capabilities
Next Generation Adjuvants
Research and development capabilities to evaluate new adjuvants, including combination adjuvants. This work is done in collaboration with leading researchers and companies in the vaccine and adjuvant space and sponsored by the National Institutes of Health.
We understand that successful pharma product development can never start too early. Using non GMP adjuvants in preclinical work that cannot progress to the clinic can prevent new therapeutics from leaving the lab. Starting with adjuvants that can be made available as GMP prevents costly experimental repetition and is attractive to funding agencies, as it prevents an often unforeseen hurdle.
What Sets EVAX Apart?
Emulsion Adjuvants: EVAX offers the only commercial mimic made with non-animal squalene that is available for preclinical through clinical (GMP) applications. See Science.
Integrated Manufacturing: Using our proprietary yeast-production system we have an integrated, US-based, production pipeline for the critical ingredient in triterpene-containing adjuvants. See Facilities.
Next Generation Adjuvants: Through the EVAX parent company, Enepret Incorporated, we have research and development capabilities to evaluate new adjuvants, including combinations. This work is done in collaboration with leading researchers and companies in the vaccine and adjuvant space and sponsored by the National Institutes of Health. Contact us for more information.
Focus on Translational Capabilities: With our scientific and manufacturing backgrounds, we understand that successful pharma product development can never start too early. Using adjuvants in preclinical work that cannot progress to the clinic (i.e., not available as GMP) can prevent new therapeutics from leaving the lab. Starting with adjuvants that can be made available as GMP prevents costly experimental repetition and is attractive to funding agencies, as it prevents an often unforeseen hurdle.